Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed cancer treatment, particularly for hematologic malignancies like acute lymphoblastic leukemia (ALL) and multiple myeloma. By engineering patients’ T cells to target specific tumor …
Chimeric Antigen Receptor T (CAR T) cell therapy is a revolutionary treatment for hematological malignancies, particularly effective against B-cell acute lymphoblastic leukemia and B-cell lymphoma. It involves genetically modifying a patient’s …
CAR-T therapy, a groundbreaking treatment for hematologic malignancies, involves genetic modification of T cells to target cancer-specific antigens. Despite its high efficacy, particularly in relapsed or refractory cases, CAR-T therapy is associated …
Follicular lymphoma is a common type of non-Hodgkin lymphoma (NHL) characterized by slow growth and primarily affects B lymphocytes in the lymphatic system. It is the most prevalent form of low-grade lymphoma, often asymptomatic in early stages, and …
Dasatinib, known as Sprycel, is a powerful tyrosine kinase inhibitor used primarily to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It targets the BCR-ABL fusion protein, disrupting …
Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma characterized by the uncontrolled growth of B lymphocytes in the mantle zone of lymph nodes. It often exhibits both indolent and aggressive traits, complicating diagnosis and …
Chemotherapy is a fundamental treatment for Hodgkin’s lymphoma, utilizing powerful drugs to kill or slow cancer cell growth. Administered in cycles via IV, oral, or intramuscular methods, it aims to maximize remission and minimize recurrence …
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in the U.S., accounting for about one-third of cases, primarily affecting older adults, especially men in their mid-60s. It involves the rapid proliferation of …
Diffuse large B-cell lymphoma (DLBCL) is a fast-growing blood cancer affecting B-lymphocytes, accounting for about 25% of non-Hodgkin lymphoma cases in the U.S. Symptoms include swollen lymph nodes, fever, night sweats, and weight loss. Diagnosis …
Epkinly is a bispecific antibody targeting CD20 and CD3, representing a promising treatment for B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL). It enhances the immune system’s ability to identify and eliminate malignant …
Trexall, known generically as methotrexate, is an effective medication for managing autoimmune diseases and certain cancers, classified as a disease-modifying anti-rheumatic drug (DMARD). It works by inhibiting folic acid metabolism, reducing …
Yescarta (axicabtagene ciloleucel) is an innovative CAR T-cell therapy designed to treat specific blood cancers, notably diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma. This treatment involves collecting a …
Epkinly (epcoritamab) is a groundbreaking treatment for diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, accounting for about 22% of new cases in the U.S. each year. This bispecific antibody targets CD3 on T …
Rydapt, or midostaurin, is an oral medication used to treat acute myeloid leukemia (AML) and systemic mastocytosis by inhibiting receptor tyrosine kinases, particularly FLT3, which is often mutated in AML. It enhances patient outcomes when combined …
Polivy (polatuzumab vedotin) is an innovative antibody-drug conjugate used in the treatment of diffuse large B-cell lymphoma (DLBCL), particularly for patients who have relapsed or are refractory to previous therapies. As the most common aggressive …
Yescarta is a revolutionary CAR T-cell therapy approved for treating adult patients with relapsed or refractory large B-cell lymphoma, particularly non-Hodgkin’s lymphoma (NHL). It works by utilizing genetically modified T cells to target and …
Hodgkin Lymphoma (HL) is a cancer of the lymphatic system characterized by Reed-Sternberg cells and is one of the most treatable cancers, particularly when diagnosed early. It includes two main types: classical Hodgkin lymphoma, which comprises 95% …
The article discusses Nodular Sclerosis Hodgkin’s Lymphoma (NSHL), highlighting its unique characteristic of Reed-Sternberg cells, which arise from B-lymphocytes. NSHL spreads predictably, starting in one lymph node group, allowing for …
Castleman disease is a rare immune dysregulation disorder characterized by abnormal lymphatic tissue overgrowth, leading to enlarged lymph nodes. It primarily manifests in two types: unicentric Castleman disease (UCD), involving a single lymph node …
Kymriah, the first FDA-approved CAR T-cell therapy, has significantly transformed cancer treatment, particularly for blood cancers like pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL). This innovative …
The article emphasizes the importance of close monitoring for patients receiving Kymriah, particularly during the initial weeks post-infusion when side effects like Cytokine Release Syndrome (CRS) and neurological toxicities are most likely. Regular …
Blincyto is a bispecific T-cell engager (BiTE) used to treat acute lymphoblastic leukemia (ALL) by targeting CD19 on B cells and CD3 on T cells, enhancing the immune system’s ability to eliminate cancer cells. The recommended dosage consists of …
Treanda, or bendamustine, is a chemotherapy agent approved by the FDA in 2008, used primarily for chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (NHL). It functions as an alkylating agent, disrupting DNA synthesis and inducing …
Truxima (rituximab-abbs) is a monoclonal antibody that targets CD20 on B-cells, effectively reducing inflammation and symptoms of autoimmune diseases like rheumatoid arthritis, lupus, and certain cancers, including non-Hodgkin lymphoma and chronic …
Poteligeo (mogamulizumab) is a monoclonal antibody targeting CCR4, primarily used for treating relapsed or refractory mycosis fungoides (MF) and Sézary syndrome, types of cutaneous T-cell lymphoma (CTCL). It recruits immune effector cells to …
The article discusses the importance of lymphocyte levels in diagnosing and managing lymphoma. Normal lymphocyte counts range from 1,000 to 4,800 cells per microliter in adults, with deviations indicating potential health issues. Elevated lymphocyte …
Neulasta, or pegfilgrastim, is a biologic medication designed to prevent neutropenia, a common side effect of chemotherapy characterized by low neutrophil counts. By stimulating bone marrow, Neulasta enhances white blood cell production, thus …
The article discusses Truxima, the first biosimilar of the biologic rituximab, highlighting its role in making healthcare treatments more affordable. Truxima, a monoclonal antibody targeting CD20 on B-cells, is effective for conditions like …
Tezspire (tezepelumab-ekko) is a groundbreaking monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), a cytokine that plays a crucial role in asthma and chronic allergic conditions. Unlike traditional biologics, Tezspire …
R-ICE (Rituximab, Ifosfamide, Carboplatin, and Etoposide) is a chemotherapy regimen primarily used for treating relapsed or refractory non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. It combines an immunotherapy component (Rituximab) with …
The article discusses the side effects, dosage guidelines, financial considerations, and patient experiences related to Carvykti, a CAR-T cell therapy for relapsed or refractory multiple myeloma. Common side effects include cytokine release syndrome …
